Zai Lab of Shanghai acquired global rights to a topical biologic treatment for inflammatory conditions developed by Crescendo Biologics (Cambridge, UK). Zai Lab will have rights to develop, commercialize and manufacture the innovative antibody VHdomain therapeutic, focusing initially on psoriasis. Crescendo received an upfront cash payment and will be eligible for development, regulatory, and commercial milestones for multiple indications, plus royalties. Zai expects to file an IND for the therapeutic candidate to begin clinical trials in psoriasis in 2019.
Source: China Biotoday
